{"slug":"nmpa-approved","tag":"nmpa-approved","variants":["nmpa-approved"],"description":"No description yet","count":12,"kinds":{"drug":12},"related":[{"slug":"china","tag":"china","shared":12}],"records":[{"id":"benmelstobart","kind":"drug","name":"Benmelstobart","route":"/drugs/benmelstobart/","status":"approved","tldr":"Benmelstobart is Chia Tai Tianqing's PD-L1 antibody, approved in China in 2024 for extensive-stage small-cell lung cancer in combination with anlotinib and chemotherapy."},{"id":"iruplinalkib","kind":"drug","name":"Iruplinalkib","route":"/drugs/iruplinalkib/","status":"approved","tldr":"Iruplinalkib is Qilu Pharmaceutical's second-generation ALK inhibitor, approved in China in 2023 for ALK-positive non-small-cell lung cancer after crizotinib and in 2024 as first-line treatment."},{"id":"flumatinib","kind":"drug","name":"Flumatinib","route":"/drugs/flumatinib/","status":"approved","tldr":"Flumatinib is Hansoh Pharma's second-generation BCR-ABL inhibitor, approved in China in 2019 for newly diagnosed chronic-phase chronic myeloid leukaemia."},{"id":"utidelone","kind":"drug","name":"Utidelone","route":"/drugs/utidelone/","status":"approved","tldr":"Utidelone is Biostar Pharmaceuticals' epothilone chemotherapy, approved in China in 2021 with capecitabine for advanced breast cancer after anthracyclines and taxanes."},{"id":"inetetamab","kind":"drug","name":"Inetetamab","route":"/drugs/inetetamab/","status":"approved","tldr":"Inetetamab is 3SBio's HER2 antibody, approved in China in 2020 with vinorelbine for HER2-positive metastatic breast cancer."},{"id":"linperlisib","kind":"drug","name":"Linperlisib","route":"/drugs/linperlisib/","status":"approved","tldr":"Linperlisib is Shanghai Yingli's PI3K-delta inhibitor, approved in China in 2022 for relapsed or refractory follicular lymphoma after two or more lines."},{"id":"surufatinib","kind":"drug","name":"Surufatinib","route":"/drugs/surufatinib/","status":"approved","tldr":"Surufatinib is HUTCHMED's angio-immuno kinase inhibitor, approved in China in 2020 for non-pancreatic and in 2021 for pancreatic neuroendocrine tumours."},{"id":"recombinant-human-endostatin","kind":"drug","name":"Recombinant human endostatin","route":"/drugs/recombinant-human-endostatin/","status":"approved","tldr":"Endostar is Simcere's recombinant endostatin, approved in China in 2005 with chemotherapy for advanced non-small-cell lung cancer, one of the first angiogenesis inhibitors approved anywhere."},{"id":"h101-oncolytic-adenovirus","kind":"drug","name":"H101 oncolytic adenovirus","route":"/drugs/h101-oncolytic-adenovirus/","status":"approved","tldr":"Oncorine is Shanghai Sunway Biotech's oncolytic adenovirus, approved in China in 2005 for nasopharyngeal carcinoma with chemotherapy, the first oncolytic virus approved anywhere in the world."},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/","status":"approved","tldr":"QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy."},{"id":"mecapegfilgrastim","kind":"drug","name":"Mecapegfilgrastim","route":"/drugs/mecapegfilgrastim/","status":"approved","tldr":"Mecapegfilgrastim is Hengrui's long-acting G-CSF, approved in China in 2018 to prevent chemotherapy-induced neutropenia."},{"id":"vorolanib","kind":"drug","name":"Vorolanib","route":"/drugs/vorolanib/","status":"approved","tldr":"Vorolanib is Betta Pharmaceuticals' oral VEGFR and PDGFR inhibitor, approved in China in 2023 with everolimus for advanced kidney cancer after a first kinase inhibitor has failed."}]}